What are the opening hours?

Monday 09:00 - 06:00 Tuesday 09:00 - 06:00 Wednesday 09:00 - 06:00 Thursday 09:00 - 06:00 Friday 09:00 - 06:00

Aston Sci.

Home
South Korea
Seoul
Aston Sci.

Aston Sci. is a clinical-stage bio-pharmaceutical company.

09/04/2024

We proudly presented our very first research poster among the six at the AACR 2024 in San Diego on April 8th. Titled "AST-05X: A novel GCN2 inhibitor for sarcoma treatment" (Abstract #1873), our presentation marked a significant milestone in our research journey. We sincerely appreciate your overwhelming interest and support! 👍

🔍 The research poster is available for download in PDF format:
https://drive.google.com/drive/folders/1K-ma4IzuX8pCcwWbtkXMtE3SatCcInXH?usp=sharing

📌 Join us today and tomorrow, April 9~10th, as we present clinical phase 1 results of AST-021p cancer vaccine and preclinical findings from other cancer vaccine pipelines.

Looking forward to meeting you and discussing further!

.

18/03/2024

🔍 Access the abstract for each of our 6 poster presentations at the AACR Annual Meeting 2024 in San Diego:

1) Abstract # CT193
Title: Phase 1 clinical trial evaluating the safety, tolerability, and immunogenicity of AST-021p, a novel cancer vaccine targeting HSP90-derived epitopes in advanced solid tumor patients (CornerStone-002)
https://www.abstractsonline.com/pp8/ #!/20272/presentation/11483
* Late-breaking and clinical trials abstract text release on April 5, 2024 at 12 p.m. PT/3 p.m. ET

2) Abstract # 6757
Title: The anti-tumor efficacy of Th1-specific TROP2 vaccine (AST-07X) in a triple-negative breast cancer murine model
https://www.abstractsonline.com/pp8/ #!/20272/presentation/5952

3) Abstract # 4112
Title: Identification of Th1-specific epitopes from non-mutated KRAS lesions for off-the-shelf cancer vaccines
https://www.abstractsonline.com/pp8/ #!/20272/presentation/5950

4) Abstract # 4113
Title: AST-301, a pDNA-based cancer vaccine encoding HER2-ICD, enhances anti-tumor effect of HER2-ADC in a HER2-expressed gastric cancer xenograft model
https://www.abstractsonline.com/pp8/ #!/20272/presentation/5949

5) Abstract # 4114
Title: AST-201 (pUMVC3-hIGFBP2 N-terminus) demonstrates anti-tumor effect in an ovarian cancer mouse model
https://www.abstractsonline.com/pp8/ #!/20272/presentation/5951

6) Abstract # 1873
Title: AST-05X: A novel GCN2 inhibitor as a promising anti-cancer approach for sarcoma
https://www.abstractsonline.com/pp8/ #!/20272/presentation/8124

Stay tuned for more updates and insights from the AACR Annual Meeting!

18/03/2024

We are excited to showcase 6 posters at the AACR Annual Meeting 2024 in San Diego! These posters cover diverse areas, including the phase 1 clinical trial results of AST-021p, a promising therapeutic cancer vaccine, along with research insights on two novel antigen-based cancer vaccines, AST-07X and AST-11X. Additionally, we are presenting recent findings on our lead drug candidates, AST-301 and AST-201, currently in phase 2 multinational clinical trials. Furthermore, we will share a significant discovery related to ISR inhibitor, AST-05X. 🔬🧪

Abstract # CT193
Phase 1 clinical trial evaluating the safety, tolerability, and immunogenicity of AST-021p, a novel cancer vaccine targeting HSP90-derived epitopes in advanced solid tumor patients (CornerStone-002)

Abstract # 6757
The anti-tumor efficacy of Th1-specific TROP2 vaccine (AST-07X) in a triple-negative breast cancer murine model

Abstract # 4112
Identification of Th1-specific epitopes from non-mutated KRAS lesions for off-the-shelf cancer vaccines

Abstract # 4113
AST-301, a pDNA-based cancer vaccine encoding HER2-ICD, enhances anti-tumor effect of HER2-ADC in a HER2-expressed gastric cancer xenograft model

Abstract # 4114
AST-201 (pUMVC3-hIGFBP2 N-terminus) demonstrates anti-tumor effect in an ovarian cancer mouse model

Abstract # 1873
AST-05X: A novel GCN2 inhibitor as a promising anti-cancer approach for sarcoma

http://astonsci.com/bbs/?so_table=press&mode=VIEW&num=85&category=&findType=&findWord=&sort1=&sort2=&page=1

08/03/2024

🌟 Today, on International Women's Day, we celebrate the remarkable achievements and contributions of women around the world. At Aston Sci., we stand proud in our commitment to promoting gender equity and equality.

💪 As we strive for breakthroughs in cancer research, including pioneering treatments for women's cancers, we recognize the pivotal role that gender equity plays in driving our industry forward.

🌍 This year's theme, "Inspire Inclusion," resonates deeply with our mission. We believe that fostering an inclusive environment not only empowers women but also drives innovation and progress for all.

07/02/2024

Happy Lunar New Year!🌙 Your support and trust mean so much to us. Your support fuels our dedication to the mission of empowering patients through innovative cancer immunotherapy. May this Year of the Blue Dragon bring you all closer to your goals, with good health and success! All the best! 새해 복 많이 받으세요! 🐉🎊

28/12/2023

Season's greetings from all of us at Aston Sci. Wishing you a prosperous New Year filled with success and happiness. 🎄✨

28/12/2023

🌐 Exciting partnership announcement in cancer vaccine innovation!

Thrilled to share that Aston Sci. has officially signed an exclusive research and license agreement with Abogen Biosciences, a clinical-stage biopharmaceutical company specializing in mRNA drug development. 🤝 This landmark collaboration grants Abogen exclusive rights to develop and commercialize the specific epitope(s) derived from Aston Sci.'s Th-Vac® platform technology into mRNA therapeutic cancer vaccine(s).

Aston Sci.'s partnership with Abogen, known for its recent Emergency Use Authorization (EUA) from The Indonesian Food and Drug Authority (BPOM) for its mRNA COVID-19 vaccine, is now propelling cancer vaccine development in Asia to new heights. 🚀

Here's the plan: Aston Sci., utilizing its Th-Vac® platform, will screen for epitopes on antigens crucial for cancer immunotherapy. Abogen, in turn, will integrate these epitopes into its own mRNA-LNP vaccine design engine, optimizing and developing the vaccine for the target indication(s).

The epitope(s) identified by Aston Sci.’s epitope discovery platform activates CD8 T cell immune responses by increasing CD4 T cell immunogenicity. The cancer vaccine incorporating such epitope(s) is expected to demonstrate clinical safety and efficacy, especially in various solid tumor conditions unresponsive to standard therapies, including immunotherapies.

This open innovation partnership signifies a major milestone in global cancer vaccine landscape. 🌟 Stay tuned for groundbreaking advancements!

15/12/2023

Sharing a special moment with "Deulggot Youth World," a youth support non-profit organization! 🌼 Congratulations to Deulggot on its 30th anniversary, marking three decades of dedication and efforts in fostering hope and positive change for countless young hearts.

Aston Sci., along with our dedicated employees, has actively participated in this project, understanding that even small contributions can bring about significant positive changes in our community.

In appreciation of our collective efforts, Deulggot has awarded us a special appreciation plaque, symbolizing the precious moments we've shared and our dedication to making a lasting impact on society.

Thank you all for being part of this experience. We look forward to your continued support!👏

[후원자 이야기] 들꽃은 저에게 ‘치유’의 의미, 고해성사의 공간 | (wahaha.or.kr)
http://wahaha.or.kr/archives/16572

07/11/2023

Meet Aston Sci.'s BD team members, Byungmin Kim and So Yoon Kim. 🤝 At BIO-Europe 2023, we're excited to showcase our innovative cancer vaccines and our groundbreaking epitope discovery platform, Th-Vac®. Our team is actively engaging in meetings, sharing insights, and discussing business opportunities and collaborations with industry leaders. 🌐

Join the meeting with us and make the most of this event together!

For more event details, visit: https://informaconnect.com/bioeurope/?utm_source=google&utm_medium=cpc&utm_campaign=tagdigital&gclid=Cj0KCQjwy4KqBhD0ARIsAEbCt6jpw9CSZIKxzA6ARlrduG0ykf2mcz8_5Y03ZnPrljQpwdZaGUkZY3kaArLaEALw_wcB

07/11/2023

We're grateful to all the industry professionals who visited us at SITC 2023 in San Diego. Your support has been invaluable! 🌟

Explore our 5 posters featuring groundbreaking research on our new antigen-based cancer vaccines AST-07X and AST-11X, along with updates on our lead drug candidates, AST-201 and AST-301. They are available online as well!

🌐 For a closer look at our work and to access abstracts, please visit the SITC 2023 website here: https://www.sitcancer.org/2023/abstracts/abstract-titles-publications?SITC%202023%20Titles%20with%20URLs%5BrefinementList%5D%5BAbstract%20Type%5D%5B0%5D=Regular

📂 To download the posters and explore them at your convenience, please use the following link: https://drive.google.com/drive/folders/1Fd_9HWkxkwIaWSGBdr7JsHbOL33tTI4k?usp=drive_link

03/11/2023

We are presenting 5 posters at SITC 2023 in San Diego! 🔬📊 They include research findings on 2 new antigen-based cancer vaccines, AST-07X and AST-11X, as well as recent findings related to our lead drug candidates, AST-201 and AST-301 cancer vaccines, which are currently undergoing phase 2 multinational clinical trials. 👩‍🔬💉

To learn more about our research and access abstracts, please visit the SITC 2023 website: https://www.sitcancer.org/2023/abstracts/abstract-titles-publications?SITC%202023%20Titles%20with%20URLs%5BrefinementList%5D%5BAbstract%20Type%5D%5B0%5D=Regular

03/11/2023

🌟 Join us for BIO-Europe, Europe's Flagship Partnering Event! Meet our BD team members, Byungmin Kim and So Yoon Kim, who will be representing Aston Sci. in Munich. They are all set to explore potential business opportunities and collaborations. At BIO-Europe 2023, we'll be showcasing our innovative cancer vaccines and our groundbreaking epitope discovery platform, Th-Vac®. We've got so much to discuss and share, and we can't wait to connect with you. 🤝🌐

Link to the event website: https://informaconnect.com/bioeurope/?utm_source=google&utm_medium=cpc&utm_campaign=tagdigital&gclid=Cj0KCQjwy4KqBhD0ARIsAEbCt6jpw9CSZIKxzA6ARlrduG0ykf2mcz8_5Y03ZnPrljQpwdZaGUkZY3kaArLaEALw_wcB

Address

10F, 40, Seolleung-ro 90-gil, Gangnam-gu
Seoul
06193

Opening Hours

Monday	09:00 - 06:00
Tuesday	09:00 - 06:00
Wednesday	09:00 - 06:00
Thursday	09:00 - 06:00
Friday	09:00 - 06:00

Telephone

+82220382347

Website

http://astonsci.com/

Alerts

Be the first to know and let us send you an email when Aston Sci. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.